Health Care [ 4/12 ] | Biotechnology [ 15/73 ]
NASDAQ | Common Stock
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases.
Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors.
Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors.
The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 7, 25 | -0.07 Increased by +43.18% | -0.11 Increased by +34.64% |
| Aug 5, 25 | -0.10 Increased by +50.00% | -0.11 Increased by +9.09% |
| May 7, 25 | -0.15 Increased by +25.00% | -0.16 Increased by +6.25% |
| Mar 17, 25 | -0.08 Increased by +77.14% | -0.13 Increased by +38.46% |
| Nov 6, 24 | -0.12 Increased by +35.16% | -0.18 Increased by +31.56% |
| Aug 6, 24 | -0.20 Increased by +37.50% | -0.17 Decreased by -17.65% |
| May 9, 24 | -0.20 Increased by +25.93% | -0.16 Decreased by -25.00% |
| Mar 19, 24 | -0.35 Decreased by -29.63% | -0.18 Decreased by -94.44% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 32.06 M Increased by +425.07% | -67.25 M Increased by +21.55% | Decreased by -209.77% Increased by +85.06% |
| Jun 30, 25 | 26.43 M Increased by +2.42 K% | -92.56 M Increased by +31.22% | Decreased by -350.26% Increased by +97.27% |
| Mar 31, 25 | 16.52 M Increased by +41.19 K% | -129.65 M Increased by +3.33% | Decreased by -784.92% Increased by +99.77% |
| Dec 31, 24 | 7.55 M Increased by +5.33 K% | -59.16 M Increased by +74.65% | Decreased by -783.40% Increased by +99.53% |
| Sep 30, 24 | 6.11 M Increased by +7.35 K% | -85.73 M Increased by +10.31% | Decreased by -1.40 K% Increased by +98.80% |
| Jun 30, 24 | 1.05 M Increased by +2.45 K% | -134.56 M Increased by +2.40% | Decreased by -12.85 K% Increased by +96.18% |
| Mar 31, 24 | 40.00 K Decreased by -88.89% | -134.11 M Decreased by -15.27% | Decreased by -335.27 K% Decreased by -937.43% |
| Dec 31, 23 | 139.00 K Increased by +90.41% | -233.39 M Decreased by -115.67% | Decreased by -167.91 K% Decreased by -13.27% |